miCheckup is miRoncol’s Real-time Multi-Cancer Early Risk Assessment — a blood-based test that detects microRNA signatures – biological signals sometimes present in early-stage solid tumours.
It provides a snapshot of your current molecular cancer risk, empowering you to discuss results with your physician and decide whether further evaluation makes sense.
Our approach combines:
Highly sensitive indicators of early cellular change
Trained on human data
Designed to assess risk across common solid tumour types
Built on peer-reviewed research and informed by large-scale studies, miRoncol provides meaningful insights you and your doctor can act on together.
miRoncol’s Real-time Multi-Cancer Early Risk Assessment is designed to identify molecular patterns linked to more than a dozen common solid tumours. Together, these cancers represent about 80% of cancer incidence in men and 40% in women in Canada.
This coverage represents the majority of cancers that impact Canadians today. While not diagnostic, miRoncol provides a meaningful pre-screen that complements existing screening programs.
Supporting Clinicians, Executive Health Teams & Preventive Care Professionals. miRoncol works with:
We help you connect to:
Our test offers a molecular pre-screen that can be incorporated into annual checkups, preventive health packages.